{"id":67651,"date":"2026-06-08T14:53:37","date_gmt":"2026-06-08T06:53:37","guid":{"rendered":"https:\/\/flcube.com\/?p=67651"},"modified":"2026-06-08T14:53:38","modified_gmt":"2026-06-08T06:53:38","slug":"eli-lillys-foundayo-orforglipron-demonstrates-significant-weight-loss-across-all-menopausal-stages-addresses-critical-gap-in-womens-metabolic-health","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67651","title":{"rendered":"Eli Lilly&#8217;s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women&#8217;s Metabolic Health"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced groundbreaking results from the <strong>ATTAIN-1 and ATTAIN-2<\/strong> clinical trials demonstrating that <strong>Foundayo (orforglipron)<\/strong>, its oral GLP-1 receptor agonist, achieved substantial weight loss across all stages of menopause in women with obesity or overweight. The data addresses a major unmet need, as menopause-related hormonal changes significantly accelerate abdominal fat accumulation and impair weight loss efforts in over 1.2 billion women globally.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results-by-menopausal-status\" class=\"wp-block-heading\">Clinical Trial Results by Menopausal Status<\/h2>\n\n\n\n<h3 id=\"h-attain-1-study-obesity-overweight-population\" class=\"wp-block-heading\">ATTAIN-1 Study (Obesity\/Overweight Population)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Menopausal Stage<\/th><th>Maximum Weight Loss (lbs)<\/th><th>Maximum Weight Loss (%)<\/th><\/tr><\/thead><tbody><tr><td><strong>Premenopausal<\/strong><\/td><td>28.0 lbs<\/td><td>12.8%<\/td><\/tr><tr><td><strong>Perimenopausal<\/strong><\/td><td>30.4 lbs<\/td><td>14.4%<\/td><\/tr><tr><td><strong>Postmenopausal<\/strong><\/td><td>28.2 lbs<\/td><td>14.1%<\/td><\/tr><tr><td><strong>\u226515% Weight Loss Achievers<\/strong><\/td><td>Up to 51.5% of participants<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-attain-2-study-type-2-diabetes-population\" class=\"wp-block-heading\">ATTAIN-2 Study (Type 2 Diabetes Population)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Menopausal Stage<\/th><th>Maximum Weight Loss (lbs)<\/th><th>Maximum Weight Loss (%)<\/th><\/tr><\/thead><tbody><tr><td><strong>Premenopausal<\/strong><\/td><td>23.4 lbs<\/td><td>11.3%<\/td><\/tr><tr><td><strong>Perimenopausal<\/strong><\/td><td>18.5 lbs<\/td><td>8.9%<\/td><\/tr><tr><td><strong>Postmenopausal<\/strong><\/td><td>27.8 lbs<\/td><td>13.6%<\/td><\/tr><tr><td><strong>\u226515% Weight Loss Achievers<\/strong><\/td><td>Up to 44.2% of participants<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-secondary-endpoints-amp-body-composition\" class=\"wp-block-heading\">Secondary Endpoints &amp; Body Composition<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Waist Circumference Reduction:<\/strong> Up to 4.9 inches (12.5 cm) in ATTAIN-1 and 4.3 inches (11.0 cm) in ATTAIN-2 at week 72<\/li>\n\n\n\n<li><strong>Abdominal Fat Targeting:<\/strong> Clinically significant reduction in visceral adiposity, addressing menopause-specific fat distribution patterns<\/li>\n\n\n\n<li><strong>Metabolic Improvements:<\/strong> Enhanced insulin sensitivity and glycemic control in diabetic cohort<\/li>\n\n\n\n<li><strong>Durability:<\/strong> Sustained weight loss maintained through 72-week treatment period<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-significance\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> 1.2 billion women globally experiencing menopause-related metabolic challenges<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> First oral GLP-1 specifically demonstrating efficacy across all menopausal stages<\/li>\n\n\n\n<li><strong>Therapeutic Gap:<\/strong> Current weight management therapies show reduced efficacy in postmenopausal women due to hormonal changes<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Premium positioning in women&#8217;s health segment of $100B+ GLP-1 market<\/li>\n\n\n\n<li><strong>Regulatory Timeline:<\/strong> NDA submission expected Q3 2026 with potential approval in H1 2027<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-scientific-innovation-amp-mechanism\" class=\"wp-block-heading\">Scientific Innovation &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral Bioavailability:<\/strong> Orforglipron represents next-generation oral GLP-1 with improved pharmacokinetic profile<\/li>\n\n\n\n<li><strong>Hormonal Interaction:<\/strong> Maintains efficacy despite estrogen decline and associated metabolic changes during menopause<\/li>\n\n\n\n<li><strong>Central vs. Peripheral Effects:<\/strong> Dual action on appetite regulation and peripheral metabolism overcomes menopausal resistance<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Favorable gastrointestinal tolerability compared to injectable GLP-1 analogs<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-context\" class=\"wp-block-heading\">Competitive Landscape Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Foundayo (Orforglipron)<\/th><th>Competing GLP-1 Therapies<\/th><\/tr><\/thead><tbody><tr><td><strong>Administration<\/strong><\/td><td>Oral daily<\/td><td>Predominantly injectable<\/td><\/tr><tr><td><strong>Menopausal Efficacy<\/strong><\/td><td>Proven across all stages<\/td><td>Limited specific data<\/td><\/tr><tr><td><strong>Abdominal Fat Reduction<\/strong><\/td><td>4.3-4.9 inches<\/td><td>Variable, less documented<\/td><\/tr><tr><td><strong>\u226515% Weight Loss Rate<\/strong><\/td><td>Up to 51.5%<\/td><td>Typically 30-40% range<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial expectations for Foundayo. Actual results may differ due to final regulatory decisions, competitive dynamics, market adoption rates, and evolving treatment guidelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":67654,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,199,911,86],"class_list":["post-67651","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-eli-lilly","tag-nyse-lly","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly&#039;s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women&#039;s Metabolic Health - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical trials demonstrating that Foundayo (orforglipron), its oral GLP-1 receptor agonist, achieved substantial weight loss across all stages of menopause in women with obesity or overweight. The data addresses a major unmet need, as menopause-related hormonal changes significantly accelerate abdominal fat accumulation and impair weight loss efforts in over 1.2 billion women globally.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67651\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly&#039;s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women&#039;s Metabolic Health\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical trials demonstrating that Foundayo (orforglipron), its oral GLP-1 receptor agonist, achieved substantial weight loss across all stages of menopause in women with obesity or overweight. The data addresses a major unmet need, as menopause-related hormonal changes significantly accelerate abdominal fat accumulation and impair weight loss efforts in over 1.2 billion women globally.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67651\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-08T06:53:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-08T06:53:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0802.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67651#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67651\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly&#8217;s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women&#8217;s Metabolic Health\",\"datePublished\":\"2026-06-08T06:53:37+00:00\",\"dateModified\":\"2026-06-08T06:53:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67651\"},\"wordCount\":401,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67651#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0802.webp\",\"keywords\":[\"Clinical trial results\",\"Eli Lilly\",\"NYSE: LLY\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67651#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67651\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67651\",\"name\":\"Eli Lilly's Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women's Metabolic Health - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67651#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67651#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0802.webp\",\"datePublished\":\"2026-06-08T06:53:37+00:00\",\"dateModified\":\"2026-06-08T06:53:38+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical trials demonstrating that Foundayo (orforglipron), its oral GLP-1 receptor agonist, achieved substantial weight loss across all stages of menopause in women with obesity or overweight. The data addresses a major unmet need, as menopause-related hormonal changes significantly accelerate abdominal fat accumulation and impair weight loss efforts in over 1.2 billion women globally.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67651#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67651\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67651#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0802.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0802.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly's Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women's Metabolic Health\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67651#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly&#8217;s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women&#8217;s Metabolic Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women's Metabolic Health - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical trials demonstrating that Foundayo (orforglipron), its oral GLP-1 receptor agonist, achieved substantial weight loss across all stages of menopause in women with obesity or overweight. The data addresses a major unmet need, as menopause-related hormonal changes significantly accelerate abdominal fat accumulation and impair weight loss efforts in over 1.2 billion women globally.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67651","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women's Metabolic Health","og_description":"Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical trials demonstrating that Foundayo (orforglipron), its oral GLP-1 receptor agonist, achieved substantial weight loss across all stages of menopause in women with obesity or overweight. The data addresses a major unmet need, as menopause-related hormonal changes significantly accelerate abdominal fat accumulation and impair weight loss efforts in over 1.2 billion women globally.","og_url":"https:\/\/flcube.com\/?p=67651","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-08T06:53:37+00:00","article_modified_time":"2026-06-08T06:53:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0802.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67651#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67651"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly&#8217;s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women&#8217;s Metabolic Health","datePublished":"2026-06-08T06:53:37+00:00","dateModified":"2026-06-08T06:53:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67651"},"wordCount":401,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=67651#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0802.webp","keywords":["Clinical trial results","Eli Lilly","NYSE: LLY","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67651#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67651","url":"https:\/\/flcube.com\/?p=67651","name":"Eli Lilly's Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women's Metabolic Health - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=67651#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=67651#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0802.webp","datePublished":"2026-06-08T06:53:37+00:00","dateModified":"2026-06-08T06:53:38+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical trials demonstrating that Foundayo (orforglipron), its oral GLP-1 receptor agonist, achieved substantial weight loss across all stages of menopause in women with obesity or overweight. The data addresses a major unmet need, as menopause-related hormonal changes significantly accelerate abdominal fat accumulation and impair weight loss efforts in over 1.2 billion women globally.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67651#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67651"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=67651#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0802.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0802.webp","width":1080,"height":608,"caption":"Eli Lilly's Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women's Metabolic Health"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67651#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly&#8217;s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages \u2013 Addresses Critical Gap in Women&#8217;s Metabolic Health"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0802.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67651"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67651\/revisions"}],"predecessor-version":[{"id":67655,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67651\/revisions\/67655"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/67654"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}